Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin-Reference-Cited by-同舟云学术

Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin

Published:2023-04 Issue:4 Volume:11 Page:1323-1325.e1
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Voelker Dayne,Bednarski Jeffrey J.,Nieman Elizabeth,Carter Melody C.,Polk Brooke

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases

University of North Carolina at Chapel Hill

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference8 articles.

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms;Khoury;Leukemia,2022

2. Molecular defects in mastocytosis: KIT and beyond KIT;Bibi;Immunol Allergy Clin North Am,2014

3. SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis;Martinelli;Leukemia,2018

4. Systemic mastocytosis with diffuse cutaneous involvement and haematological disease presenting in utero treated unsuccessfully with vincristine;Angus;Clin Exp Dermatol,2008

5. In utero presentation of aggressive systemic mastocytosis in a neonate;Huang;Br J Dermatol,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lack of response to midostaurin in a patient with vulvar melanoma harboring an unusual KIT D816Y mutation that emerged after a previous treatment with imatinib;EJC Skin Cancer;2023